The global market for Dipeptidyl Peptidase-4 (DPP-4) inhibitors, used in type 2 diabetes treatment, is projected to grow from $11.28 billion in 2025 to $15.53 billion by 2032, at a CAGR of 5.47%. Growth is fueled by the ongoing global burden of type 2 diabetes, demand for oral glucose-lowering therapies, and increasing availability of generics and fixed-dose combinations. While newer diabetes therapies like GLP-1 receptor agonists and SGLT2 inhibitors pose competitive pressure, DPP-4 inhibitors remain relevant due to their ease of use, low hypoglycemia risk, and weight-neutral profile. North America leads the market, followed by Europe and Asia Pacific, with key players including Merck, AstraZeneca, and Boehringer Ingelheim. The market outlook emphasizes affordability, access expansion, and simplified treatment regimens amid evolving competition.
Shares of key players in the DPP-4 inhibitors market show mixed trends on Pluang. Merck (MRK) trades at USD 141.74, down 0.74%, while AstraZeneca (AZN) is at USD 158.33, down 1.12%. Takeda (TAK) is up 0.38% at USD 18.44. These prices reflect investor activity as of Oct 09, 2026 01:42 WIB.
On October 7, HP, Merck, and Seagate each paid their quarterly dividends, highlighting different approaches to rewarding shareholders. Merck paid the highest dividend per share at $0.85, reflecting its strong pharmaceutical business and growth, despi...
A Dutch court ruled that Merck infringed Halozyme's MDASE patent EP622 and ordered Merck's affiliate MSD BV to stop manufacturing, selling, and importing Keytruda SC in several European countries. The injunction covers Belgium, Denmark, France, Irela...
Moderna shares surged 8% to $204.60 as investors anticipate the full Phase 3 melanoma vaccine trial data to be presented at the European Society for Medical Oncology (ESMO) congress in Madrid. The vaccine, developed with Merck, showed promising resul...
